Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1149-1160

  Hsi, Linda C ^a,b   Kundu, Suman ^a   Palomo, Juan ^a   Xu, Bo ^a   Ficco, Ryan ^a   Vogelbaum, Michael A ^a   Cathcart, Martha K ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 HYDROPEROXIDE OCTADECADIENOIC ACID; 15 LIPOXYGENASE 1; ANTINEOPLASTIC AGENT; ARACHIDONATE 15 LIPOXYGENASE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SMALL INTERFERING RNA; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE SILENCING; GLIOBLASTOMA; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; CELL DEATH; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LIGANDS; MICE; MICE, NUDE; PPAR GAMMA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 79960145100     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1064     Document Type: Article

References (50)

1. Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Binger DD, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009;13:701-18.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62:753-64; discussion 264-6.
4. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-21.
5. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009;18:1061-83.
6. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Putel M, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15:4401-14.
7. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44. (Pubitemid 350002884)
8. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508-18. (Pubitemid 46606332)
9. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009;19:713-23.
10. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol 2009;19:694-712.
11. Liu H, Prayson RA, Estes ML, Drazba JA, Barnett GH, Bingaman W, et al. In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine 2000;12:1656-61.
12. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity on an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 2004;10:6231-8. (Pubitemid 39287531)
13. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
14. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor α chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000;60:1168-72. (Pubitemid 30151975)
15. Nishimura Y, Nitto T, Inoue T, Node K. STAT6 mediates apoptosis of human coronary arterial endothelial cells by interleukin-13. Hypertens Res 2008;31:535-41. (Pubitemid 351597508)
16. Kawakami M, Kawakami K, Puri RK. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002;1:999-1007.
17. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009;69:8678-85.
18. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006;74:479-504.
19. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002; new surprises in the Jak/Stat pathway. Cell 2002;109Suppl:S121-31.
20. Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK. Il-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J Leukoc Biol 2002;72:580-9.
21. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673-9.
22. Chiaramonte MG, Mentink-Kane M, Jacobson BA,, Cheever AW, Whitters MJ, Goad ME, et al. Regulation and function of the interleukin 13 receptor α2 during a T helper cell type 2-dominant immune response. J Exp Med 2003;197:687-701. (Pubitemid 36350864)
23. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002;62:1103-9.
24. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid, SAHA, induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 2004;64:8778-81. (Pubitemid 39552097)
25. Hsi LC, Xi X, Wu Y, Lippman SM. The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase- 1 in colorectal cancer cells. Mol Cancer Ther 2005;4:1740-6. (Pubitemid 41685308)
26. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, et al. The 15-lipoxygenase-1 product 13-S-hydorxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cells. Proc Natl Acad Sci U S A 2003;100:9968-73. (Pubitemid 37087052)
27. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, et al. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 2008;16:886-92. (Pubitemid 351587098)
28. Hsi LC, Wilson L, Nixon J, Eling TE. 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferators-activated receptor via the MAPK signaling pathway. J Biol Chem 2001;276:34545-52.
29. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, et al. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000;92:1136-42.
30. Bull AW, Steffensen KR, Leers J, Rafter JJ. Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR gamma. Carcinogenesis 2003;24:1717-22. (Pubitemid 37419906)
31. Strakova N, Ehrmann J, Dzubak P, Bouchal J, Kolar Z. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 2004;309:1239-47. (Pubitemid 38669715)
32. Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, et al. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol 2006;70:1524-33.
33. Grommes C, Landreth GE, Schlegel U, Heneka MT. The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J Pharmacol Exp Ther 2005;313:806-13. (Pubitemid 40604182)
34. Roy B, Cathcart MK. Induction of 15-lipoxygenase expression by IL-13 requires tyrosine phosphorylation of Jak2 and Tyk2 in human monocytes. J Biol Chem 1998;273:32023-9. (Pubitemid 29177143)
35. Xu B, Bhattacharjee A, Roy B, Xu HM, Anthony D, Frank DA, et al. Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3. Mol Cell Biol 2003;23:3918-28. (Pubitemid 36597470)
36. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845-53. (Pubitemid 36800831)
37. Guo D, Wang B, Han F, Lei T. RNA interference therapy for glioblastoma. Expert Opin Biol Ther 2010;10:927-36.
38. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62. (Pubitemid 41724921)
39. Lage H. Therapeutic potential of RNA interference in drug-resistant cancers. Future Oncol 2009;5:169-85.
40. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-84.
41. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-9. (Pubitemid 44764213)
42. Kioi M, Sarawathy S, Puri RK. Targeting IL-13Rα2-positive cancer with novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 2008;7:1579-87.
43. Bram H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Rel 2001;74:63-7. (Pubitemid 32727609)
44. Vandergrift WA, Patel SJ, Nicholas JS, Varma AK. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus 2006;20:E13.
45. Nguyen TT, Pannu YS, Sung C, Dedrick RL, Walbridge S, Brechbiel MW, et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003;98:584-90. (Pubitemid 36262780)
46. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004;10:3667-77. (Pubitemid 38697600)
47. RES in infected cell cultures. PLoS One 2010;5:e11085.
48. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43. (Pubitemid 47037001)
49. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96.
50. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)